{"protocolSection":{"identificationModule":{"nctId":"NCT05697185","orgStudyIdInfo":{"id":"KY-0012"},"organization":{"fullName":"Second Affiliated Hospital of Guangxi Medical University","class":"OTHER"},"briefTitle":"Safety and Efficacy of Evolocumab in Ischemic Stroke","officialTitle":"Safety and Efficacy of Evolocumab in in Combination With Statin Therapy in Adults With Ischemic Stroke","acronym":"SEEIS"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-02-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-02-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-01-15","studyFirstSubmitQcDate":"2023-01-15","studyFirstPostDateStruct":{"date":"2023-01-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-01-15","lastUpdatePostDateStruct":{"date":"2023-01-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Junli Liang","investigatorTitle":"Professor","investigatorAffiliation":"Second Affiliated Hospital of Guangxi Medical University"},"leadSponsor":{"name":"Second Affiliated Hospital of Guangxi Medical University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this clinical trial is to evaluate the effect of evolocumab in combination with statin therapy (atorvastatin) in acute ischemic stroke (AIS)."},"conditionsModule":{"conditions":["Ischemic Stroke, Acute"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"the evolocumab plus statin therapy","type":"EXPERIMENTAL","description":"Patients with AIS are treated with atorvastatin (40mg) daily and evolocumab (420 mg) every months throughout the study period","interventionNames":["Drug: Evolocumab"]},{"label":"the statin alone therapy","type":"NO_INTERVENTION","description":"Patients with AIS are treated with atorvastatin (40mg) daily throughout the study period."}],"interventions":[{"type":"DRUG","name":"Evolocumab","description":"Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.","armGroupLabels":["the evolocumab plus statin therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent change in LDL-C","timeFrame":"baseline, 4 weeks, 8 weeks, 12 weeks after treatment"}],"secondaryOutcomes":[{"measure":"Vascular events","description":"incidence of Transient ischemic attack, stroke or other vascular events","timeFrame":"3 months, 6months"},{"measure":"mRS (0-2)","description":"proportion of mRS (0-2)","timeFrame":"3 months, 6months"},{"measure":"death of any causes","description":"proportion of death","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient age between 18-80 years\n2. Time of onset: within 1 week\n3. NIHSS score ≤12\n4. Acute ischemic stroke confirmed by head CT or MRI\n5. Premorbid mRS ≤1\n6. Signed informed consent\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage found by head CT\n2. Severe hepatic or renal dysfunction\n3. Pregnant females\n4. Abnormal elevation of creatine phosphokinase\n5. Blood sugar is out of control\n6. Receiving statins within 1 month before onset\n7. Not willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures\n8. Unsuitable for this clinical studies assessed by researcher","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Junli Liang, PhD","role":"CONTACT","phone":"+86-13481138068","email":"liangjl80@163.com"}],"overallOfficials":[{"name":"Junli Liang, PhD","affiliation":"The Second Affiliated Hospital of Guangxi Medical University, Nanning, China","role":"STUDY_DIRECTOR"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000577155","term":"Evolocumab"}],"ancestors":[{"id":"D000091362","term":"PCSK9 Inhibitors"},{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000057847","term":"Lipid Regulating Agents"}],"browseLeaves":[{"id":"M351","name":"Atorvastatin","relevance":"LOW"},{"id":"M348089","name":"Evolocumab","asFound":"Parental","relevance":"HIGH"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M2850","name":"PCSK9 Inhibitors","relevance":"LOW"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}